FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Biologics

Regenerative Stem Cell Institute Unapproved Cell Products

FDA says the Elgin-IL-based Regenerative Stem Cell Institute is marketing cellular products without an approved BLA or IND.

Biologics

High Bar for Vaccine Liability Claims

Three Morrison Foerster attorneys say a recent Connecticut federal court decision in a case involving Mercks Gardasil demonstrates there is a high bar...

Human Drugs

Closer Drug Postapproval Monitoring Needed: Researchers

Harvard Medical School researchers say FDA should clearly indicate when it has extrapolated an approved drug indication from pivotal trial data.

Human Drugs

No CDER Objection to Covis Materials for Makena Hearing

CDER says it doesnt object to additional materials Covis Pharma wants to introduce at a hearing on the FDA proposal to withdraw approval for Makena bu...

Medical Devices

False Results in Some Prenatal Screening Tests

FDA cautions that noninvasive prenatal screening tests can give false results that can lead to inappropriate decisions without a confirmatory diagnost...

Human Drugs

PI3K Briefing Document Reiterates FDA Concerns

FDA reiterates concerns with phosphatidylinositol 3-kinase (PI3K) inhibitors and their approval for treating hematological malignancies.

Human Drugs

Center for Rare Neurological Diseases Warned on 2 Trials

FDA warns the Norcross, GA-based Center for Rare Neurological Diseases about human subject protection violations in its conduct of two clinical trials...

Federal Register

Published Literature Used for Animal Drugs Guide

Federal Register notice: FDA makes available a draft guidance for industry #106 entitled The Use of Published Literature in Support of New Animal Drug...

Federal Register

FDA Corrects ANDA Withdrawal Notice

Federal Register notice: FDA corrects a 2/28 notice announcing the withdrawal of approval of five ANDAs from multiple applicants.

Human Drugs

CGMP Violations at Vi-Jon Facility

FDA warns St. Louis, MO-based Vi-Jon about CGMP violations in its production of finished drugs.